DrugPatentWatch Database Preview
Par Pharm Company Profile
What is the competitive landscape for PAR PHARM, and when can generic versions of PAR PHARM drugs launch?
PAR PHARM has two hundred and fourteen approved drugs.
There is one US patent protecting PAR PHARM drugs. There are fourteen tentative approvals on PAR PHARM drugs.
There are nine patent family members on PAR PHARM drugs in eight countries and one hundred and twenty-two supplementary protection certificates in twelve countries.
Summary for Par Pharm
| International Patents: | 9 |
| US Patents: | 1 |
| Tradenames: | 128 |
| Ingredients: | 125 |
| NDAs: | 214 |
| Patent Litigation for Par Pharm: | See patent lawsuits for Par Pharm |
| PTAB Cases with Par Pharm as petitioner: | See PTAB cases with Par Pharm as petitioner |
Drugs and US Patents for Par Pharm
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Par Pharm | TESTOSTERONE | testosterone | GEL;TRANSDERMAL | 076744-001 | May 23, 2007 | AB1 | RX | No | No | ➤ Sign Up | ➤ Sign Up | ||||
| Par Pharm | QUETIAPINE FUMARATE | quetiapine fumarate | TABLET, EXTENDED RELEASE;ORAL | 090482-004 | May 9, 2017 | AB | RX | No | No | ➤ Sign Up | ➤ Sign Up | ||||
| Par Pharm | METHYCLOTHIAZIDE | methyclothiazide | TABLET;ORAL | 089136-001 | Feb 12, 1986 | DISCN | No | No | ➤ Sign Up | ➤ Sign Up | |||||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
Expired US Patents for Par Pharm
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Par Pharm Inc | ACCOLATE | zafirlukast | TABLET;ORAL | 020547-001 | Sep 26, 1996 | 4,859,692 | ➤ Sign Up |
| Par Pharm | CAPOTEN | captopril | TABLET;ORAL | 018343-007 | Jun 13, 1995 | 4,258,027 | ➤ Sign Up |
| Par Pharm | CAPOTEN | captopril | TABLET;ORAL | 018343-004 | Jun 13, 1995 | 4,105,776 | ➤ Sign Up |
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
Paragraph IV (Patent) Challenges for PAR PHARM drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Nasal Spray | 500 mcg/spray | ➤ Subscribe | 2017-04-28 |
| ➤ Subscribe | Tablets | 10 mg and 20 mg | ➤ Subscribe | 2008-02-29 |
International Patents for Par Pharm Drugs
| Country | Document Number | Estimated Expiration |
|---|---|---|
| World Intellectual Property Organization (WIPO) | 2006115626 | ➤ Sign Up |
| South Korea | 20080000660 | ➤ Sign Up |
| Canada | 2605413 | ➤ Sign Up |
| Country | Document Number | Estimated Expiration |
Supplementary Protection Certificates for Par Pharm Drugs
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| 2014 00048 | Denmark | ➤ Sign Up | PRODUCT NAME: KOMBINATION AF ROSUVASTATIN OG EZETIMIBE ELLER FARMACEUTISK ACCEPTABLE SALTE DERAF, HERUNDER ROSUVASTATIN SOM ZINK; NAT. REG. NO/DATE: 52921, 52922, 52923 20140820; FIRST REG. NO/DATE: NO 13-9663, 13-9664, 13-9665 20140724 |
| C0030 | France | ➤ Sign Up | PRODUCT NAME: EPROSARTAN MESYLATE; HYDROCHLOROTHIAZIDE; NAT. REGISTRATION NO/DATE: NL 32075 20060623; FIRST REGISTRATION: LI - 55783 01 20020607 |
| 595 | Luxembourg | ➤ Sign Up | PRODUCT NAME: SIMEPREVIR, OU L UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES, INCLUANT SIMEPREVIR SODIUM. FIRST REGISTRATION: 20140516 |
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.
